You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (8) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (9) Apply Biologicals filter
- Blood and blood components (4) Apply Blood and blood components filter
- Remove Complementary medicines filter Complementary medicines (22)
- Cosmetics (2) Apply Cosmetics filter
- Disinfectants/Sterilants (4) Apply Disinfectants/Sterilants filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (23) Apply Labelling/Packaging filter
- Legislation (20) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Manufacturing (11) Apply Manufacturing filter
- Medical devices safety (1) Apply Medical devices safety filter
- Medical devices/IVDs (48) Apply Medical devices/IVDs filter
- Medicinal cannabis (1) Apply Medicinal cannabis filter
- Medicines (1) Apply Medicines filter
- Remove OTC medicines filter OTC medicines (31)
- Prescription medicines (25) Apply Prescription medicines filter
- Safety of medicines & medical devices (2) Apply Safety of medicines & medical devices filter
- Scheduling (37) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (6) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (6) Apply Therapeutic goods regulation filter
Permissible ingredients annual changes 2020-21
Closed on 6 October 2020
Benzocaine: proposed advisory statements for medicines
Closed on 16 October 2018
Options for the implementation of a claimer for efficacy assessed non-prescription medicines
Closed on 21 June 2018
Discontinuing pre-market evaluation of Herbal Component Names (HCNs)
Closed on 12 January 2018
Business process improvements supporting complementary medicines assessment pathways
Closed on 7 November 2017
Reforms to the regulatory framework for complementary medicines: Assessment pathways
Closed on 28 March 2017
Non-steroidal anti-inflammatory drugs: proposed additional advisory statement
Closed on 22 November 2016
Paracetamol and ibuprofen: advisory statements for medicines
Closed on 22 November 2016
cimetidine, famotidine, nizatidine and ranitidine: corrected advisory statement for medicines
Closed on 29 October 2015